Spain’s Grifols said the latest results from a clinical trial of the company’s Alzheimer’s treatment show positive effects by achieving a reduction of the disease’s progression in patients with mild and moderate conditions.

The U.S. Food and Drug Administration approved ADMA Biologics’ Asceniv to treat primary humoral immunodeficiency disease (PIDD or PI) in adults and adolescents.

Argenx and Halozyme Therapeutics signed a global collaboration and license deal that allows Argenx to use Halozyme’s Enhanze drug delivery technology to develop multiple products.

Alexion Pharmaceuticals is acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn), for a total value of up to $1.2 billion.

As Shire’s acquisition by Takeda Pharmaceutical approaches, the global biotechnology company reported a solid second-quarter 2018.